{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(6)"],"submitter":["Ling QS"],"pubmed_abstract":["Stroke is a common cause of death and disability. Allisartan isoproxil (ALL) is a new angiotensin II receptor blocker and a new antihypertensive drug discovered and developed in China. In the present study we investigated the therapeutic effects of ALL in stroke-prone renovascular hypertensive rats (RHR-SP) and the underlying mechanisms. The model rats were generated via two-kidney two-clip (2K2C) surgery, which led to 100% of hypertension, 100% of cerebrovascular damage as well as 100% of mortality 1 year after the surgery. Administration of ALL (30 mg · kg<sup>-1</sup> · d<sup>-1</sup> in diet, for 55 weeks) significantly decreased stroke-related death and prolonged lifespan in RHR-SP, but the survival ALL-treated RHR-SP remained of hypertension and cardiovascular hypertrophy compared wi"],"journal":["Acta pharmacologica Sinica"],"pagination":["871-884"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8149727"],"repository":["biostudies-literature"],"pubmed_title":["Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage."],"pmcid":["PMC8149727"],"pubmed_authors":["Fu FH","Tian JS","Zhang SL","Liu JG","Miao CY","Liu AJ","Ling QS","Cheng MH"],"additional_accession":[]},"is_claimable":false,"name":"Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage.","description":"Stroke is a common cause of death and disability. Allisartan isoproxil (ALL) is a new angiotensin II receptor blocker and a new antihypertensive drug discovered and developed in China. In the present study we investigated the therapeutic effects of ALL in stroke-prone renovascular hypertensive rats (RHR-SP) and the underlying mechanisms. The model rats were generated via two-kidney two-clip (2K2C) surgery, which led to 100% of hypertension, 100% of cerebrovascular damage as well as 100% of mortality 1 year after the surgery. Administration of ALL (30 mg · kg<sup>-1</sup> · d<sup>-1</sup> in diet, for 55 weeks) significantly decreased stroke-related death and prolonged lifespan in RHR-SP, but the survival ALL-treated RHR-SP remained of hypertension and cardiovascular hypertrophy compared wi","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-04T20:15:19.789Z","creation":"2025-04-04T20:15:19.789Z"},"accession":"S-EPMC8149727","cross_references":{"pubmed":["34002042"],"doi":["10.1038/s41401-021-00684-7"]}}